Medicare Part D Formulary Exclusion Events
Regulatory
Buy side
Sell side
Feasibility
Extracted facts
Research report
Demand Research Report: Medicare Part D Formulary Exclusion Events
Generated: 2026-04-19T15:21:26.735937 Event ID: medicare_part_d_formulary_exclusions
Executive Summary
| Metric | Value |
|---|---|
| Verdict | WEAK_DEMAND |
| Confidence | 35% |
| Companies Exposed | 0 |
After exhaustive investigation, the claim that there is strong demand for hedging Medicare Part D formulary exclusion risk is NOT substantiated. The fundamental premise is flawed: the risk description confuses WHO bears formulary exclusion risk. CVS and Walgreens cited in the claim are actually PBMs (Pharmacy Benefit Managers) and retail pharmacies that MAKE formulary decisions—they don't suffer from them. The entities actually exposed are pharmaceutical MANUFACTURERS (Eli Lilly, Novo Nordisk, AbbVie, Pfizer) whose drugs get excluded.
Key findings: (1) Drug manufacturers face real revenue risk—Eli Lilly's Zepbound exclusion from CVS formularies in 2025 caused immediate stock decline and material revenue impact. (2) However, manufacturers show NO evidence of seeking to hedge this risk through derivatives. They manage it through rebate negotiations, multiple product portfolios, and pricing strategies. (3) Retail pharmacies (CVS, Walgreens) face different risks—reimbursement rate pressure and DIR fees—not formulary exclusions per se. (4) The claimed '10-30% revenue impact' statistic is unsourced and appears to conflate different risks. (5) Most critically, no insurance or hedging products exist for this risk, and companies have not disclosed spending on such protection.
The correct market opportunity would be hedging pharmaceutical manufacturer formulary exclusion risk, not retail pharmacy risk. But even for manufacturers, there's limited evidence of hedging demand—they prefer operational responses over financial derivatives.
Company-by-Company Analysis
CVS Health Corporation (CVS)
Exposure: CVS Health OPERATES the Caremark PBM that makes formulary decisions and owns retail pharmacies. Their exposure is to reimbursement rate pressure, not formulary exclusions. They decide what gets excluded, not suffer from exclusions.
Quantified Impact: 2025 total revenue $402.1B. Retail pharmacy segment faces reimbursement pressure but no specific formulary exclusion exposure disclosed. The company IS the decision-maker on formularies through Caremark PBM.
10-K Risk Factor Quote (2026-02-10):
No risk factor found regarding suffering from formulary exclusions. CVS operates both sides: they run the PBM making formulary decisions AND own retail pharmacies dispensing drugs.
Current Hedging: No evidence of hedging formulary exclusion risk. CVS manages PBM business through rebate negotiations with manufacturers and manages retail pharmacy margins through integrated model.
Walgreens Boots Alliance (WBA)
Exposure: Walgreens operates retail pharmacies exposed to third-party reimbursement rate pressure, DIR fees, and generic substitution requirements. NOT directly exposed to formulary exclusion decisions—they dispense whatever is on formulary.
Quantified Impact: FY2024 revenue $147.7B. Pharmacy reimbursement pressure is material but distinct from formulary exclusion risk. Facing broader retail pharmacy profitability crisis.
10-K Risk Factor Quote (2024-10-15):
Risk factors discuss 'continued reimbursement pressure in our U.S. Retail Pharmacy business' but this relates to reimbursement RATES, not formulary exclusions.
Current Hedging: No evidence of derivatives hedging. Company managing through store closures, cost reduction, and footprint optimization program (announced 2024).
Eli Lilly and Company (LLY)
Exposure: ACTUAL formulary exclusion exposure. When CVS excluded Zepbound from preferred formularies in favor of Novo's Wegovy in 2025, Lilly faced material revenue impact from reduced patient access.
Quantified Impact: Zepbound/Mounjaro generated $17.6B in Q3 2025 alone. CVS formulary decision affected access for millions of covered lives. Stock declined on May 1, 2025 following CVS formulary announcement.
10-K Risk Factor Quote (2026-02-04):
No specific 10-K quote found, but company disclosed in earnings calls that formulary access negotiations with PBMs are material to revenue forecasts.
Current Hedging: No evidence of financial hedging. Company responded through pricing negotiations, patient assistance programs, and attempting to maintain access through rebates. Operational response only.
Novo Nordisk (NVO)
Exposure: Pharmaceutical manufacturer with formulary exclusion risk for Wegovy and Ozempic. Benefited when CVS chose Wegovy over Lilly's Zepbound, but faces exclusion risk on other formularies.
Quantified Impact: 2025 revenue 729.4B DKK (~$105B USD). US rebates/discounts totaled 394.6B DKK in 2025, showing massive PBM negotiation exposure. Company warned of 'unprecedented price pressure' in Feb 2026 guidance.
10-K Risk Factor Quote (2026-02-04):
Company discloses 'US Managed Care and Medicare' rebates as separate line item, indicating material exposure to payer coverage decisions.
Current Hedging: No evidence of derivatives hedging. Manages through geographic diversification, therapeutic area diversification, and aggressive rebate programs.
AbbVie Inc. (ABBV)
Exposure: Suffered material formulary exclusion impact when CVS and Express Scripts excluded Humira from preferred lists in 2024, favoring biosimilars. This is the clearest historical example of formulary exclusion financial impact.
Quantified Impact: Humira had 2023 global revenue of $14.4B (declining from $21.2B in 2022). Formulary exclusions by major PBMs in 2024 accelerated US erosion. Company explicitly disclosed volume erosion from formulary positioning.
10-K Risk Factor Quote (2025-02-07):
Company earnings releases state 'biosimilar competition' and 'formulary positioning' as material factors. Q3 2024: 'volume erosion to worsen' due to formulary changes.
Current Hedging: No derivatives hedging evident. Company strategy was to launch new products (Skyrizi, Rinvoq) to replace Humira revenue and negotiate aggressively on biosimilar pricing.
Historical Events
| Date | Event | Impact | Companies |
|---|---|---|---|
| 2025-05-01 | CVS Caremark announced Eli Lilly's Zepbound would ... | LLY stock declined on announcement; exact % not disclosed in available data but described as 'wobbled' and 'weakened' in news coverage | LLY, NVO |
| 2024-01-03 | CVS announced removal of AbbVie's Humira from some... | Contributed to ongoing Humira revenue erosion; ABBV disclosed 'volume erosion' expected to worsen in subsequent quarters | ABBV |
| 2024-08-26 | Cigna/Express Scripts announced Humira formulary e... | Part of broader -36.4% decline in Humira US revenue from 2022 to 2024 | ABBV |
| 2026-01-29 | Big Three PBMs (CVS Caremark, Express Scripts, Opt... | No specific stock event identified, but industry-wide impact on numerous manufacturers | Multiple pharmaceutical manufacturers |
| 2025-04-07 | CMS finalized 2026 Medicare Advantage and Part D p... | TGT -7.27%, HD -5.27%, LOW -5.20% (Note: these are RETAILERS, not pharmacies—likely data error in stock event matching) | TGT, HD, LOW |
Market Sizing
| Metric | Value |
|---|---|
| Companies Exposed | 3-5 major pharmaceutical manufacturers with blockbuster drugs at formulary risk (Eli Lilly, Novo Nordisk, AbbVie identified). NOT retail pharmacies as claimed. Potentially 20-30 mid-size pharma companies with secondary exposure. |
| Combined Market Cap | ~$1.2 trillion (LLY $650B, NVO $400B, ABBV $300B as of early 2026) |
| Annual Revenue at Risk | $50-100B estimated aggregate revenue exposed to formulary positioning across top manufacturers. Individual drugs can have $10-20B annual sales at risk (e.g., Wegovy, Mounjaro, pre-biosimilar Humira). |
Methodology: Market cap from public data. Revenue at risk calculated from disclosed sales of drugs subject to formulary negotiations (obesity drugs, immunology biologics, specialty medications). Note: This is potential revenue influenced by formulary position, not binary loss—most excluded drugs still accessible at higher cost or through appeals.
Proposed Contract Structure
| Attribute | Value |
|---|---|
| Type | Binary outcome difficult; parametric more feasible |
| Trigger | Could be binary: 'Is Drug X on preferred tier of PBM Y's Medicare Part D formulary for plan year Z?' Verified from CMS Medicare Plan Finder database. Alternative parametric: Market share change following formulary publication. |
| Resolution Source | CMS.gov Medicare Plan Finder database and official formulary publications from PBMs. Data is public and verifiable. Formularies published annually in October-November for following plan year. |
| Settlement | Binary settlement if drug achieves/loses preferred status. Challenges: (1) Multiple PBMs with different formularies, (2) Mid-year formulary changes possible, (3) 'Preferred' vs 'covered' vs 'excluded' creates multiple tiers not pure binary, (4) Determining which specific drug/indication pair to cover in contract. |
Existing Hedging Alternatives
NO existing hedging products identified. This is critical negative evidence. Pharmaceutical manufacturers manage formulary risk through: (1) Rebate negotiations with PBMs offering discounts of 40-85% off list price, (2) Patient assistance programs, (3) Product portfolio diversification across therapeutic areas, (4) Geographic diversification outside US, (5) Lifecycle management launching new formulations. Insurance industry does not offer formulary coverage insurance. No OTC derivatives market exists. Performance-based risk-sharing agreements with payers exist but these are different—tied to clinical outcomes, not formulary placement itself. The absence of any existing hedging despite massive financial stakes ($50-100B annual revenue exposed) suggests manufacturers prefer operational flexibility over financial hedges, or that the risk is too idiosyncratic/negotiable to hedge efficiently.
Supporting Evidence
10K Risk Factor
🟢 Novo Nordisk 20-F
- Company: Novo Nordisk
- Date: 2026-02-04
- US Managed Care and Medicare rebates/discounts totaled 394.6B DKK in 2025, representing the largest single discount category. Company warned of 'unprecedented price pressure' affecting 2026 outlook.
- Source
🟢 CVS Health 10-K
- Company: CVS Health
- Date: 2025-02-08
- CVS operates both PBM (Caremark) making formulary decisions AND retail pharmacies. Risk factors focus on regulatory changes, Medicare Advantage pressure, NOT on being subject to formulary exclusions made by others.
- Source
Analyst
🟡 Milliman Consulting
- Date: 2025-01-01
- Analysis of IRA impact on Part D formulary negotiations notes that manufacturers must adapt contracting strategies. No mention of derivatives or insurance products—focus entirely on rebate and access negotiations.
- Source
Hedging
🟢 Multiple company 10-Ks reviewed
- Company: All pharmaceutical manufacturers
- Date: 2024-2026
- No evidence found of any pharmaceutical manufacturer disclosing use of derivatives, insurance products, or financial hedging specifically for formulary exclusion risk. All manage operationally through rebates, pricing, and portfolio strategies.
News
🟢 Drug Channels Institute
- Date: 2026-01-01
- For 2026, the three largest PBMs—Caremark (CVS Health), Express Scripts (Cigna), and Optum Rx (UnitedHealth Group)—have each excluded more than 600 drugs from their formularies. This represents the largest exclusion lists to date.
- Source
🟢 Reuters
- Company: Eli Lilly
- Date: 2025-05-01
- Eli Lilly downplays CVS move to drop Zepbound coverage. Shares in Eli Lilly weakened after CVS Health, one of the largest PBMs in the US, said it would no longer cover its obesity therapy Zepbound on preferred formularies.
- Source
🟢 Reuters
- Company: AbbVie
- Date: 2024-01-03
- CVS will remove AbbVie's Humira from some drug reimbursement lists in April. CVS Health will exclude AbbVie's blockbuster arthritis drug Humira from some of its reimbursement lists starting April, favoring lower-cost biosimilars.
- Source
🟢 CNBC
- Company: CVS Health, Walgreens
- Date: 2024-08-18
- Retail pharmacy chains facing 'falling reimbursement rates' as biggest challenge, leading to hundreds of store closures. This is distinct from formulary exclusion risk—it's about reimbursement RATES for drugs that are on formulary.
- Source
🟢 FTC Staff Report
- Date: 2024-07-01
- FTC report on PBMs describes how 'powerful middlemen' negotiate formulary positions and rebates, confirming PBMs make formulary decisions that affect manufacturers, not retailers.
- Source
Stock Event
🟡 Stock price data
- Company: Eli Lilly
- Date: 2025-05-01
- Lilly stock declined following CVS announcement that Zepbound would be excluded from preferred formularies in favor of Novo Nordisk's Wegovy. Company had to revise revenue expectations.
Detailed Analysis
This research reveals a fundamental mismatch between the claimed hedging opportunity and actual market structure. The claim positioned this as retail pharmacy/drug retail risk (CVS, Walgreens), but these companies are on the SUPPLY side of formulary decisions, not the demand side.
The real formulary exclusion risk sits with pharmaceutical MANUFACTURERS. Eli Lilly's experience with Zepbound demonstrates clear material impact: when CVS excluded it from preferred formularies in 2025, the stock price declined and the company faced revenue pressure on a multi-billion dollar product. AbbVie's Humira erosion accelerated dramatically when major PBMs excluded it in favor of biosimilars in 2024. These are real, quantifiable business events.
However, even with clear exposure, manufacturers show ZERO evidence of seeking financial hedges. Several factors explain this: (1) Formulary decisions are negotiable—unlike weather or commodity prices, manufacturers can influence outcomes through rebates and pricing, (2) Outcomes are not binary—drugs move between preferred/non-preferred tiers rather than covered/excluded entirely in most cases, (3) Risk is company-specific and product-specific, making standardized contracts difficult, (4) Manufacturers prefer operational responses (rebates, new formulations, portfolio diversification) over financial hedges.
The claimed '10-30% revenue impact' statistic could not be verified and appears to confuse different types of risk. Retail pharmacies do face reimbursement pressure (DIR fees, rate cuts) but this is conceptually different from formulary exclusions. The evidence shows retail pharmacy profit pressure comes from how much they're PAID to dispense drugs on formulary, not from drugs being excluded.
For a Prophet derivatives contract to succeed, it would need: (1) Pharmaceutical manufacturers as buyers (not retail pharmacies), (2) Clear binary triggers (specific drug on specific PBM's preferred formulary), (3) Value proposition beyond what rebate negotiations already provide, (4) Standardization despite highly idiosyncratic risk. The challenge is that manufacturers appear to prefer keeping formulary negotiations flexible and relationship-based rather than financializing them.
Confidence is LOW (0.35) because while formulary changes clearly impact stock prices and revenues, there's no demonstrated demand for financial hedges and significant structural barriers to creating a liquid market.
Report generated by Prophet Heidi Research Pipeline